切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2023, Vol. 12 ›› Issue (03) : 168 -171. doi: 10.3877/cma.j.issn.2095-3216.2023.03.009

综述

血液透析患者的血压靶目标值研究进展
李晓晨, 乔晞()   
  1. 030001 太原,山西医科大学第二医院、山西省肾脏病研究所、山西医科大学肾脏病研究所
  • 收稿日期:2022-08-01 出版日期:2023-06-28
  • 通信作者: 乔晞
  • 基金资助:
    山西省回国留学人员科研资助项目(2020-186); 山西省留学回国人员科技活动择优资助项目(2017-29)

Progress of research on target value of blood pressure in patients undergoing hemodialysis

Xiaochen Li, Xi Qiao()   

  1. Department of Nephrology, Second Hospital of Shanxi Medical University, Shanxi Provincial Institute for Kidney Disease, Kidney Disease Institute of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
  • Received:2022-08-01 Published:2023-06-28
  • Corresponding author: Xi Qiao
引用本文:

李晓晨, 乔晞. 血液透析患者的血压靶目标值研究进展[J]. 中华肾病研究电子杂志, 2023, 12(03): 168-171.

Xiaochen Li, Xi Qiao. Progress of research on target value of blood pressure in patients undergoing hemodialysis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(03): 168-171.

血液透析(HD)是目前全球范围内使用最为普遍的肾脏替代治疗方式。HD患者死亡的首要原因是心血管系统疾病,而后者与患者血压水平密切相关。因此,血压控制非常重要。目前国内外对HD患者血压管理的靶目标值尚未有统一的意见。本文就HD患者血压管理的靶目标值与临床预后之间的关系研究进展进行了综述。

Hemodialysis (HD) is the most widely used renal replacement therapy in the world. The first cause of death in HD patients is cardiovascular disease, which is closely related to the blood pressure. Blood pressure control is very important. At present, there is no unified opinion on the target value of blood pressure management in HD patients in the world. This article reviewed the progress of research on relationship between target value of blood pressure management and clinical prognosis in HD patients.

表1 血液透析患者的血压靶目标值
[1]
Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease [J]. Lancet, 2021, 398(10302): 786-802.
[2]
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet, 2020, 395(10225): 709-733.
[3]
Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories [J]. Lancet, 2018, 392(10159): 2052-2090.
[4]
Jankowski J, Floege J, Fliser D, et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options [J]. Circulation, 2021, 143(11): 1157-1172.
[5]
Jager KJ, Kovesdy C, Langham R, et al. A single number for advocacy and communication - worldwide more than 850 million individuals have kidney diseases [J]. Kidney Int, 2019, 96(5): 1048-1050.
[6]
Sarafidis PA, Persu A, Agarwal R, et al. Hypertension in dialysis patients: a consensus document by the European renal and cardiovascular medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the hypertension and the kidney working group of the European Society of Hypertension (ESH) [J]. J Hypertens, 2017, 35(4): 657-676.
[7]
Pecoits-Filho R, Okpechi IG, Donner JA, et al. Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes [J]. Kidney Int Suppl, 2020, 10(1): e3-e9.
[8]
中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者高血压管理指南(2023年版)[J]. 中华肾脏病杂志2023, 39(1): 48-80.
[9]
Thompson S, James M, Wiebe N, et al. Cause of death in patients with reduced kidney function [J]. J Am Soc Nephrol, 2015, 26(10): 2504-2511.
[10]
Bello AK, Okpechi IG, Osman MA, et al. Epidemiology of haemodialysis outcomes [J]. Nat Rev Nephrol, 2022, 18(6): 378-395.
[11]
Georgianos PI, Agarwal R. Blood pressure in hemodialysis: targets? [J]. Curr Opin Nephrol Hypertens, 2017, 26(6): 523-529.
[12]
Flythe JE, Chang TI, Gallagher MP, et al. Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference [J]. Kidney Int, 2020, 97(5): 861-876.
[13]
Turner JM, Peixoto AJ. Blood pressure targets for hemodialysis patients [J]. Kidney Int, 2017, 92(4): 816-823.
[14]
中国医药教育协会肾病与血液净化专业委员会血液透析低血压防治专家组.血液透析中低血压防治专家共识(2022) [J]. 中华内科杂志2022, 61(3): 269-281.
[15]
Miskulin DC, Gassman J, Schrader R, et al. BP in dialysis: results of a pilot study [J]. J Am Soc Nephrol, 2018, 29(1): 307-316.
[16]
Van Buren PN. Evaluation and treatment of hypertension in end-stage renal disease patients on hemodialysis [J]. Curr Cardiol Rep, 2016, 18(12): 125.
[17]
Zager PG, Nikolic J, Brown RH, et al. " U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc [J]. Kidney Int, 1998, 54(2): 561-569.
[18]
Robinson BM, Tong L, Zhang J, et al. Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study [J]. Kidney Int, 2012, 82(5): 570-580.
[19]
Hannedouche T, Roth H, Krummel T, et al. Multiphasic effects of blood pressure on survival in hemodialysis patients [J]. Kidney Int, 2016, 90(3): 674-684.
[20]
Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients [J]. Am J Kidney Dis, 1999, 33(3): 507-517.
[21]
Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions [J]. Hypertension, 2005, 45(4): 811-817.
[22]
Li Z, Lacson E Jr, Lowrie EG, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients [J]. Am J Kidney Dis, 2006, 48(4): 606-615.
[23]
Bansal N, McCulloch CE, Lin F, et al. Blood pressure and risk of cardiovascular events in patients on chronic hemodialysis: the CRIC study (Chronic Renal Insufficiency Cohort) [J]. Hypertension, 2017, 70(2): 435-443.
[24]
Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis [J]. Hypertension, 2009, 53(5): 860-866.
[25]
Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials [J]. Lancet, 2009, 373(9668): 1009-1015.
[26]
Zoccali C, Mallamaci F. Cardiovascular protection by β-blockade in hypertensive haemodialysis patients: the hypertension in haemodialysis patients treated with atenolol or lisinopril (HDPAL) trial [J]. Nephrol Dial Transplant, 2014, 29(3): 483-485.
[27]
Quencer KB, Oklu R. Hemodialysis access thrombosis [J]. Cardiovasc Diagn Ther, 2017, 7(Suppl 3): S299-S308.
[28]
McCallum W, Sarnak MJ. Blood pressure target for the dialysis patient [J]. Semin Dial, 2019, 32(1): 35-40.
[29]
Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006 [J]. Am J Kidney Dis, 2006, 48(Suppl 1): S2-S90.
[30]
National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update [J]. Am J Kidney Dis, 2015, 66(5): 884-930.
[31]
Jindal K, Chan CT, Deziel C, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology [J]. J Am Soc Nephrol, 2006, 17(3 Suppl 1): S1-S27.
[32]
Hirakata H, Nitta K, Inaba M, et al. Japanese Society for Dialysis Therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis [J]. Ther Apher Dial, 2012, 16(5): 387-435.
[33]
Davenport A, Cox C, Thuraisingham R. Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension [J]. Kidney Int, 2008, 73(6): 759-764.
[34]
SPRINT Research Group; Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control [J]. N Engl J Med, 2015, 373(22): 2103-2116.
[35]
Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease [J]. Kidney Int, 2021, 99(3): 559-569.
[36]
中华医学会肾脏病学分会,中关村肾病血液净化创新联盟. 中国透析患者慢性心力衰竭管理指南[J]. 中华肾脏病杂志2022, 38(5): 465-496.
[37]
高血压肾病诊治中国专家共识组成员. 高血压肾病诊断和治疗中国专家共识(2022) [J]. 中华高血压杂志2022, 30(4): 307-317.
[1] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[2] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[3] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[4] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[5] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[6] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[7] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[8] 江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[9] 卢艳军, 马健, 白鹏宇, 郭凌宏, 刘海义, 江波, 白文启, 张毅勋. 纳米碳在腹腔镜直肠癌根治术中253组淋巴结清扫的临床效果[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 473-477.
[10] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
[11] 胡宝茹, 尚乃舰, 高迪. 中晚期肝细胞癌的DCE-MRI及DWI表现与免疫治疗预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 399-403.
[12] 陆萍, 邹健. 凝血和纤维蛋白溶解标志物的动态变化对急性胰腺炎患者预后的评估价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 427-432.
[13] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[14] 王军, 刘鲲鹏, 姚兰, 张华, 魏越, 索利斌, 陈骏, 苗成利, 罗成华. 腹膜后肿瘤切除术中大量输血患者的麻醉管理特点与分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 844-849.
[15] 索利斌, 刘鲲鹏, 姚兰, 张华, 魏越, 王军, 陈骏, 苗成利, 罗成华. 原发性腹膜后副神经节瘤切除术麻醉管理的特点和分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 771-776.
阅读次数
全文


摘要